Valuation : AstraZeneca PLC

Market Cap 253B 217B 204B 186B 349B 23,884B 350B 2,422B 936B 12,231B 948B 928B 38,959B P/E 2026 *
20.9x
P/E 2027 * 18.3x
Enterprise Value 272B 234B 220B 201B 376B 25,724B 377B 2,609B 1,008B 13,174B 1,021B 999B 41,961B EV / Sales 2026 *
4.3x
EV / Sales 2027 * 3.95x
Free-Float
96.63%
Yield 2026 *
2.06%
Yield 2027 * 2.19%
1 day+0.59%
1 week+0.19%
Current month+0.19%
1 month+3.16%
3 months-9.92%
6 months-12.14%
Current year-8.04%
1 week 1,513.5
Extreme 1513.5
1,587.5
1 month 1,470.5
Extreme 1470.5
1,612
Current year 1,467
Extreme 1467
1,925.5
1 year 1,365
Extreme 1365
1,925.5
3 years 1,226
Extreme 1226
1,925.5
5 years 960.3
Extreme 960.3
1,925.5
10 years 461.3
Extreme 461.3
1,925.5
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Compliance Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+0.71%+0.19% - - 252B
-0.88%-2.15%+58.05%+105.26% 1,024B
-1.15%+2.68%+54.25%+74.19% 663B
-1.44%+0.38%+20.65%+76.13% 453B
-0.95%+0.23%+30.91%+37.78% 352B
-3.18%+1.78%+22.62%+41.55% 304B
+0.30%+0.67%+0.60%+11.25% 252B
-1.55%+1.11%+54.15%+75.59% 236B
+0.02%+2.24%-13.83%-55.80% 206B
-0.15%+3.65%+31.24%+103.39% 187B
Average -0.82%+1.26%+28.74%+52.15% 408.71B
Weighted average by Cap. -0.94%+0.62%+37.66%+66.90%

Financials

2026 *2027 *
Net sales 63.28B 54.42B 51.19B 46.72B 87.39B 5,985B 87.67B 607B 235B 3,065B 238B 232B 9,762B 66.87B 57.5B 54.08B 49.37B 92.34B 6,324B 92.64B 641B 248B 3,238B 251B 246B 10,315B
Net income 12.02B 10.34B 9.72B 8.87B 16.6B 1,137B 16.65B 115B 44.55B 582B 45.13B 44.15B 1,854B 13.7B 11.78B 11.08B 10.12B 18.92B 1,296B 18.98B 131B 50.79B 664B 51.45B 50.33B 2,114B
Net Debt 19.46B 16.74B 15.74B 14.37B 26.88B 1,841B 26.96B 187B 72.15B 943B 73.09B 71.49B 3,002B 11.79B 10.14B 9.54B 8.7B 16.28B 1,115B 16.33B 113B 43.7B 571B 44.27B 43.3B 1,819B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-09-07 SEK 1,566.50 +0.71% 662,738
26-09-04 SEK 1,555.50 -0.96% 544,344
26-09-03 SEK 1,570.50 +0.64% 502,662
26-09-02 SEK 1,560.50 +0.32% 594,091
26-09-01 SEK 1,555.50 -0.51% 742,928
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
162.34USD
Average target price
212.94USD
Spread / Average Target
+31.17%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!